Physician profile
Nathaniel David Burnham
NPI 1548880842
$2,611.63
in general payments reported to CMS, 2019-2025
24 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.80 · 2023: $157 · 2024: $791 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $447.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.71 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $272.39 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $199.69 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $186.55 | 2024-2025 | |
| Exact Sciences Corporation | $171.57 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $146.40 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $135.73 | 2023-2025 | Jardiance, Kisunla, Zepbound |
| Abbvie INC. | $129.77 | 2022-2025 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.96 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $67.33 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $57.96 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.31 | 2025 | Caplyta |
| Eisai INC. | $40.45 | 2025 | |
| Merck Sharp & Dohme LLC | $36.56 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $34.20 | 2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $31.10 | 2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.41 | 2025 | Rexulti |
| Boston Scientific Corporation | $24.42 | 2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $23.75 | 2025 | |
| Dexcom, INC. | $21.68 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $19.93 | 2024 | |
| Sumitomo Pharma America, INC. | $18.15 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.